An EHR interface inventory is a structured list of the external systems, data exchange workflows, and message standards a prospective EHR must support in everyday operations. It answers the professional research question directly by forcing buyers to name each interface, identify the technical specification, and request evidence from the vendor rather than accepting broad promises of interoperability. The approach combines the feature categories in public health vendor evaluation guidance with the protocol-level questions in ONC demonstration toolkits. Because interface capabilities vary by site, the inventory should be built around specific patient flows, such as electronic lab reporting, immunization registry exchange, or device capture, and then scored against the same scenario for every vendor under review [1][6].

Why an Inventory Starts with Named Workflows, Not Feature Lists

A credible inventory begins by identifying the external connections a clinic already depends on. The Kansas Local Health Department EHR Implementation Toolkit illustrates this with concrete Kansas workflows: electronic case reporting to KS Epitrax using HL7 electronic initial case report standards, an HIE connection to KHIN through XDS.b, and Bright Futures template reporting [1]. These are not generic capabilities; they are named systems and specific exchange patterns that a vendor must either support or build. A buyer can copy only the workflows that match its own operations, but the structure shows how precise an inventory should be.

The ONC Health IT Playbook reinforces that EHR systems are not one-size-fits-all and directs practices to assess their specific needs before comparing vendors [5]. An interface inventory translates that principle into an operational artifact. Instead of asking whether a product supports interoperability, the buyer asks whether it can send an immunization message in the HL7 version the state registry accepts, or whether lab results arrive as discrete data rather than scanned documents. These distinctions determine whether clinicians can use the data for decision support and reporting, which makes them material to the purchase decision.

Mapping Interface Types to Standards and Vendors

The NextGen Healthcare interfaces page demonstrates how one vendor describes its supported categories: document interfaces through the proprietary NextGen Rosetta HL7 solution, immunization registry interfaces formatted to HL7 v2.3 or v2.5, lab interfaces on HL7 v2.3 or v2.5 with adjustments for Quest and LabCorp, and PACS/RIS interfaces for systems such as ScImage, GE, and FUJI [3]. The vendor also names medical device integrations, including Hillrom HeartCentrix, GE CardioSoft, and Medtronic, plus more than 150 ophthalmology device interfaces [3]. These vendor claims should be verified against the buyer's inventory, not accepted as proof of compatibility.

The ONC 2024 Interoperability Standards Advisory supplies the standards-level reference for this mapping. It identifies HL7 Version 2.5.1 implementation guides for electronic laboratory reporting to public health and laboratory results interfaces, and lists FHIR US Lab Report as an emerging standard in pilot with feedback requested [4]. A buyer evaluating a lab interface can therefore ask whether the vendor implements the production HL7 2.5.1 guide or an emerging FHIR specification, and whether the public health reporting workflow is federally required in its setting. The ISA is explicitly informational and non-binding, so its adoption levels do not by themselves establish that a vendor has implemented a listed standard [4].

A Ten-Line Inventory Template with Scored Evidence

A working inventory can be assembled in ten lines: interface name; external system or trading partner; workflow trigger; message direction; standard and version; implementation guide; production or emerging status from the ISA; vendor response with the stated HL7 version or integration method; scored evidence from a demonstration scenario; and post-live verification plan [1][4][6]. For each row, the vendor response should be attributed to the named vendor and checked against the ONC standards advisory, where applicable.

The Kansas toolkit recommends reading through feature lists, searching online, and discussing important features with vendors and other public health agencies before inserting them into an evaluation tool [1]. That source also stresses the difficulty of vendor evaluation, which argues for keeping the inventory narrow enough to complete honestly. A buyer who cannot verify a post-live verification plan for a registry interface, for example, should mark that row as unresolved rather than treating the vendor's statement as confirmation.

Turning Vendor Claims into Testable Scenarios

The EHR Demonstration Scenario, Evaluation, and Vendor Questions toolkit offers a method for converting interface claims into observable demonstrations. It instructs buyers to provide identical pre-populated patient information to each vendor and to evaluate every vendor with the same matrix [6]. The toolkit's additional questions include whether the vendor submits insurance claims electronically, provides clinical summaries per visit, and connects to health information exchanges [6]. These questions can be adapted into interface-specific probes: ask the vendor to walk through an incoming lab result, an outgoing immunization message, and a summary exchange with an external provider.

A useful hypothetical evaluation, labeled as a suggestion rather than a tested protocol, is to take one patient with diabetes, hypertension, and GERD from the ONC scenario and follow the data exchange path at three points: the lab order leaving the EHR, the result returning from an external laboratory, and the immunization record transmitted to a registry [6]. Score each vendor on whether the message is discrete, which HL7 version is used, and whether any manual translation is required. This approach produces comparable evidence across vendors without inventing efficacy or compliance conclusions, because the scenario is a documented demonstration exercise, not a certification outcome.

Evidence Limits and What the Inventory Cannot Establish

Several limitations constrain what an interface inventory can prove. The Kansas toolkit is written for local health departments and names Kansas-specific connections such as KS Epitrax and KHIN; those names should not be generalized as market-wide requirements [1]. The NextGen page describes one vendor's stated interface categories, but it does not document independent performance data, customer counts, pricing, or implementation outcomes [3]. A buyer cannot infer that an interface exists at a particular site or performs adequately at scale from a vendor's marketing description alone.

The NIST usability protocol distinguishes interface design evaluation from validation testing with representative users performing realistic tasks [2]. That distinction matters for software buyers: a vendor may demonstrate that a message can be generated in a scripted walkthrough, but the inventory does not establish how the interface behaves under real workflow variation, error conditions, or user interaction patterns. Where the interface touches patient safety or regulatory reporting, a consequential interpretation may require formal usability testing, user-centered design review, and domain-expert examination beyond the scope of a pre-purchase inventory [2].